Previous / Next

[20120320. Complications of EMR/ESD (75): Bleeding (39) - warfarin (7) heparin coverage]

°íÀ§ÇèȯÀÚÀÇ °íÀ§Çè½Ã¼ú¿¡¼­ heparin cover¸¦ Çϵµ·Ï µÇ¾î Àִµ¥ ¾î¶»°Ô ÇØ¾ß ÇÏ´Â °ÍÀϱî¿ä?

2002³â ASGE guideline¿¡´Â ¾Æ·¡¿Í °°ÀÌ ¾º¿© ÀÖ½À´Ï´Ù.

1. The decision to administer iv heparin once the INR falls below the therapeutic level --> individualized.

2. Heparin, if used, should be discontinued 4 to 6 hours before the scheduled procedure and may be resumed 2 to 6 hours after the procedure.

3. Warfarin therapy may generally be resumed the night of the procedure.

4. Risk of major hemorrhage after EST is between 10% and 15% if anticoagulation is reinstituted within 3 days of the EST (Sandofer 1999).

5. Heparin/Warfarin overlap: for a period of 4 to 5 days or until the INR has achieved the target therapeutic range for 2 to 3 days.


2002³â ASGE guidelineÀ» º¸¸é¼­ ¸î °¡Áö ±Ã±ÝÁõÀÌ »ý°å½À´Ï´Ù. ESD 4½Ã°£ ÈÄ¿¡ IV heparinÀ» ½áµµ ÁÁÀ»±î? ESD ´çÀÏ Àú³á warfarinÀ» °æ±¸Åõ¿©Çصµ ÁÁÀ»±î? INRÀÌ target range¿¡ µµ´ÞÇÑ ÈÄ 2ÀϾ¿À̳ª heparinÀ» ½á¾ß ÇÒ±î? ¿©·¯ºÐµµ ´Ùµé ºñ½ÁÇÑ Áú¹®À» °¡Áú °ÍÀÔ´Ï´Ù. Á¤´äÀº ¾ø´Ù°í »ý°¢ÇÕ´Ï´Ù. ±×·¯³ª Àú´Â ¾Æ·¡¿Í °°ÀÌ »ý°¢ÇÏ°í ¶Ç ±×·¸°Ô ÇÏ°í ÀÖ½À´Ï´Ù.

ÁÖÀÎÀå ÀÇ°ß 1. ESD 4½Ã°£ ÈÄ¿¡ IV heparinÀ» ½áµµ ÁÁÀ»±î? º¸Åë ESD ´çÀÏÀº heparinÀ» ¾²Áö ¾Ê½À´Ï´Ù. ¾ÆÁÖ °íÀ§Ç豺¿¡¼­´Â Àú³á¿¡ SQ heparinÀ» ¾²±âµµ ÇÕ´Ï´Ù.

ÁÖÀÎÀå ÀÇ°ß 2. ESD ´çÀÏ Àú³á warfarinÀ» °æ±¸Åõ¿©Çصµ ÁÁÀ»±î? º¸Åë µå¸®°í ÀÖ½À´Ï´Ù. Àú³á ´Ê°Ô ¿ÍÆĸ°À» Æò¼Ò À¯Áö¿ë·®À¸·Î µå½Ãµµ·Ï ÇÏ°í ÀÖ½À´Ï´Ù. Loading±îÁö´Â ÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù.

ÁÖÀÎÀå ÀÇ°ß 3. INRÀÌ target range¿¡ µµ´ÞÇÑ ÈÄ 2ÀϾ¿À̳ª heparinÀ» ½á¾ß ÇÒ±î? ´ë°­ target¿¡ Á¢±ÙÇϸé Åð¿ø½ÃÅ°°í ÀÖ½À´Ï´Ù.


[Âü°í ÀÚ·á]

1) EndoTODAY ¿ÍÆĸ°

2) Ç×Ç÷¼ÒÆÇÁ¦ Antiplatelets - ³»½Ã°æ ȤÀº Á¶Á÷°Ë»ç Àü ¾Æ½ºÇǸ°, Ç×Ç÷¼ÒÆÇÁ¦¸¦ ²÷À» °ÍÀΰ¡?

3) »õ·Î¿î Ç×ÀÀ°íÁ¦ New oral anticoagulant (NOAC)

4) Ç×Ç÷¼ÒÆÇÁ¦, Ç×ÀÀ°íÁ¦ Áß´Ü Áöħ (»ï¼º¼­¿ïº´¿ø 2011)

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà